drugset / Trial / NCT01853124

Summary

The objective of this study is to determine for previously healthy children who present to a Canadian Emergency Department (ED) with acute gastroenteritis (infection or irritation of the digestive tract); if compared with placebo, the administration of a probiotic agent (Lacidofil) will result in a significantly lower proportion of children developing moderate to severe disease over the subsequent 2 weeks and will not be associated with a significantly greater occurrence of side effects.

Timeline

Start
2013-11
Primary completion
2017-05
Completion
2017-05

Outcome

Missed primary endpoint

paper CONCLUSIONS: In children who presented to the emergency department with gastroenteritis, twice-daily administration of a combined L. rhamnosus-L. helveticus probiotic did not prevent the development of moderate-to-severe gastroenteritis within 14 days after enrollment. PMID 30462939 ↗

paper trial-group assignment did not predict moderate-to-severe gastroenteritis (odds ratio, 1.06; 95% CI, 0.76 to 1.49; P=0.74). PMID 30462939 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lacidofil Other / unclassified 4e+09 cells Oral

Indications